Lineage Cell Therapeutics, Inc. (LCTX)

Lineage Therap (LCTX) Stock Price & Analysis


LCTX Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.02 - $1.79
Previous Close$1.28
Average Volume (3M)341.41K
Market Cap
Enterprise Value$173.21M
Total Cash (Recent Filing)$46.81M
Total Debt (Recent Filing)$3.64M
Price to Earnings (P/E)-9.2
Aug 10, 2023
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding170,173,789
10 Day Avg. Volume319,164
30 Day Avg. Volume341,407
Standard Deviation0.17
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)89.34
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue14.62
Enterprise Value/Gross Profit12.39
Enterprise Value/Ebitda-1.08
Price Target Upside310.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4



Risk Analysis

Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Lineage Cell Therapeutics, Inc.’s price range in the past 12 months?
Lineage Cell Therapeutics, Inc. lowest stock price was $1.02 and its highest was $1.79 in the past 12 months.
    What is Lineage Cell Therapeutics, Inc.’s market cap?
    Currently, no data Available
    When is Lineage Cell Therapeutics, Inc.’s upcoming earnings report date?
    Lineage Cell Therapeutics, Inc.’s upcoming earnings report date is Aug 10, 2023 which is in 69 days.
      How were Lineage Cell Therapeutics, Inc.’s earnings last quarter?
      Lineage Cell Therapeutics, Inc. released its earnings results on May 11, 2023. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.038 by $0.008.
        Is Lineage Cell Therapeutics, Inc. overvalued?
        According to Wall Street analysts Lineage Cell Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Lineage Cell Therapeutics, Inc. pay dividends?
          Lineage Cell Therapeutics, Inc. pays a Notavailable dividend of $0.11 which represents an annual dividend yield of N/A. See more information on Lineage Cell Therapeutics, Inc. dividends here
            What is Lineage Cell Therapeutics, Inc.’s EPS estimate?
            Lineage Cell Therapeutics, Inc.’s EPS estimate is -$0.04.
              How many shares outstanding does Lineage Cell Therapeutics, Inc. have?
              Lineage Cell Therapeutics, Inc. has 170,173,780 shares outstanding.
                What happened to Lineage Cell Therapeutics, Inc.’s price movement after its last earnings report?
                Lineage Cell Therapeutics, Inc. reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.038. Following the earnings report the stock price went down -2.128%.
                  Which hedge fund is a major shareholder of Lineage Cell Therapeutics, Inc.?
                  Among the largest hedge funds holding Lineage Cell Therapeutics, Inc.’s share is Raffles Associates Lp. It holds Lineage Cell Therapeutics, Inc.’s shares valued at 2M.


                    Lineage Therap Stock Smart Score

                    The Lineage Therap stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                    Learn more about TipRanks Smart Score

                    Company Description

                    Lineage Cell Therapeutics, Inc.

                    Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Alameda, CA.


                    Top 5 ETFs holding LCTX

                    Market Value
                    Smart Score
                    Vanguard Total Stock Market ETF
                    iShares Core S&P Total U.S. Stock Market ETF
                    Up to five ETFs with an Outperform Smart Score that hold LCTX. The ETFs are listed according to market value of LCTX within the ETF


                    Forecast EPS vs Actual EPS

                    Similar Stocks
                    Price & Change
                    Kala Pharmaceuticals
                    Plus Therapeutics

                    Popular Stocks

                    What's Included in PREMIUM?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis